Agios Pharmaceuticals, Inc.
Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines in the field of cellular metabolism and adjacent areas of biology. The company offers PYRUKYND (mitapivat) an activator of both wild-type and …
Biotechnology
US, Cambridge [HQ]
Financials
Analysts
Wall Street · Earnings · Institutional SentimentA comprehensive analysis section that covers unveiling insights about Agios Pharmaceuticals, Inc.'s gradings, price targets and earnings estimates. None
| FY | EPS | Revenue [mil.] | Profit [mil.] | EBITDA [mil.] | EBIT [mil.] | Expenses · SGA [mil.] | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| E | E | E | E | E | E | |||||||
| 2015 | -1.5900 | -2.600 | 65 | 81 | -53 | -101 | -52 | -98 | -154 | -102 | 19 | 35 |
| 2016 | -3.1500 | -5.242 | 59 | 58 | -117 | -209 | -115 | -202 | -260 | -211 | 35 | 54 |
| 2017 | -5.0700 | -6.424 | 69 | 46 | -198 | -309 | -195 | -303 | -421 | -315 | 50 | 147 |
| 2018 | -6.7500 | -6.143 | 43 | 82 | -314 | -366 | -314 | -358 | -613 | -384 | 71 | 260 |
| 2019 | -6.0300 | -6.981 | 94 | 116 | -346 | -415 | -338 | -407 | -362 | -430 | 114 | 368 |
| 2020 | -6.6100 | -4.674 | 117 | 199 | -396 | -341 | -394 | -313 | -426 | -332 | 132 | 165 |
| 2021 | -4.8600 | 25.514 | 203 | 0.56 | -335 | 37,630 | -326 | -1,981 | -316 | -2,133 | 149 | 1 |
| 2022 | 26.5500 | -6.290 | 0 | 13 | 1,604 | -299 | -337 | -292 | -397 | -426 | 121 | 44 |
| 2023 | -1.3600 | -6.258 | 14 | 27 | -74 | -352 | -380 | -291 | -389 | -435 | 121 | 87 |
| 2024 | -6.3300 | 11.442 | 26 | 35 | -352 | 621 | -384 | -21 | -391 | -21 | 119 | 111 |
| 2025 | - | -6.126 | - | 95 | - | -324 | - | -57 | - | -57 | - | 302 |
| 2026 | - | 2.F11X/td> | - | 2.F11X/td> | - | 2.F11X/td> | - | 2.F111/td> | - | 2.F111 | - | 2.F111 |
| 2027 | - | 1.F12X/td> | - | 1.F12X/td> | - | 1.F12X/td> | - | 1.F121/td> | - | 1.F121 | - | 1.F121 |
| 2028 | - | 0.F13X/td> | - | 0.F13X/td> | - | 0.F13X/td> | - | 0.F131/td> | - | 0.F131 | - | 0.F131 |